PROM1 and cancer: Furthermore, LS-1-2 significantly reduced the proportion of CD133+ cancer stem cells in HCT116/self cells (from 85.6% to 71.5%) and in patient-derived cell lines (PDC1: from 2.1% to 0.5%; PDC4: from 17.7% to 8.6%; Figure S5H).